Deep Dive Into CME Gr Stock: Analyst Perspectives (8 Ratings) - CME Group (NASDAQ:CME)

8 analysts have expressed a variety of opinions on CME Gr (NASDAQ:CME) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	1	5	1	1
Last 30D	1	0	0	0
1M Ago	0	1	1	0
2M Ago	0	0	0	0
3M Ago	0	4	0	1

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $213.88, with a high estimate of $235.00 and a low estimate of $187.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.64%.

Exploring Analyst Ratings: An In-Depth Overview

An in-depth analysis of recent analyst actions unveils how financial experts perceive CME Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Richard Repetto	Piper Sandler	Lowers	Overweight	$235.00	$250.00
Kyle Voigt	Keefe, Bruyette & Woods	Maintains	Market Perform	$226.00	$226.00
Kenneth Worthington	JP Morgan	Lowers	Underweight	$187.00	$206.00
Benjamin Budish	Barclays	Raises	Equal-Weight	$228.00	$226.00
Craig Siegenthaler	B of A Securities	Raises	Neutral	$216.00	$209.00
Kenneth Worthington	JP Morgan	Raises	Neutral	$206.00	$198.00
Kyle Voigt	Keefe, Bruyette & Woods	Raises	Market Perform	$226.00	$222.00
Andrew Bond	Rosenblatt	Raises	Sell	$187.00	$185.00

Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CME Gr. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CME Gr compared to the broader market.
Price Targets: Analysts predict movements in price targets, offering estimates for CME Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CME Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on CME Gr analyst ratings.

Get to Know CME Gr Better

Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The CME was founded in 1898 and in 2002 completed its initial public offering. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival, CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX in 2018, it has also expanded into cash foreign exchange, fixed income trading, and collateral optimization.

Financial Milestones: CME Gr's Journey

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: CME Gr's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 3.21%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: CME Gr's net margin is impressive, surpassing industry averages. With a net margin of 56.75%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.13%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.65%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMECME Group Inc

$263.870.03%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.